Blastic plasmacytoid dendritic cell neoplasms (BPDCN) are rare, aggressive haematological malignancies originating from precursors of plasmacytoid dendritic cells. Characterised by cutaneous, bone ...
“Our findings demonstrate that the mutational landscape of BPDCN is similar to that observed in other myeloid neoplasms, and we identified CCDC50 as a potential biomarker for this disease.” “Our ...
The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN ...
The rising incidence of cancer worldwide has led to an increasing number of surgeries that involve the removal of lymph nodes ...
Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in ...